Luteinizing Hormone-Releasing Hormone Agonist Therapy and Iodine I 125 Implant in Treating Patients With Previously Untreated Prostate Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically or cytologically confirmed prostate cancer
• * Previously untreated disease
• Intermediate-risk disease, as defined by the following:
• * Clinical stage \< T2c
• * Prostate-specific antigen (PSA) ≤ 20 ng/mL
• * Gleason score \< 8
• PATIENT CHARACTERISTICS:
• ECOG performance status 0-1
• Life expectancy ≥ 3 months
• Leukocyte count ≥ 3,000/uL
• Hemoglobin ≥ 10.0 g/dL
• Platelet count ≥ 100,000/uL
• Serum creatinine ≤ 2.0 mg/dL
• ALT and AST ≤ 100 IU/L
• No other cancer requiring treatment
• No poorly controlled hypertension (i.e., diastolic blood pressure ≥ 120 mm Hg)
• No severe psychiatric disorders, including schizophrenia or dementia
• No poorly controlled diabetes
• Considered appropriate for study participation, as determined by the Principal Investigator or Clinical Investigator
• PRIOR CONCURRENT THERAPY:
• No prior drugs for benign prostatic hyperplasia (other than antiandrogen therapy)
• No prior surgery for prostate cancer
• No concurrent steroid drugs (except for ointment)
• No other concurrent antiandrogen therapy